Metabolomic Signatures of Myocardial Glucose Uptake on Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography.
Metabolomic Signatures of Myocardial Glucose Uptake on Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography.
复制标题
DOI：
10.1016/j.jacbts.2022.09.011
复制
发表时间：
2022-12
影响因子：
9.7
通讯作者：
Selvaraj, Senthil
中科院分区：
文献类型：
--
作者：
Vidula, Mahesh K.;Kelly, Daniel P.;Md, Zoltan Arany;Margulies, Kenneth B.;Shah, Svati H.;Cappola, Thomas P.;Bravo, Paco E.;Selvaraj, Senthil
2022年12月：1264-1266在所有57次FDG-PET扫描中，分别为0.83 （95% CI: 0.65-1.00）和0.81 (95% CI: 0.70-0.92)，相应的优势比为每SD增加的MGS为4.93 （95% CI: 0.62-39.43）和9.59 （95% CI: 3.54-25.97）。虽然我们之前发现BHB在KD组和KE组分别获得了可比较的C统计数据，但BHB在联合模型中不能预测（C统计量：0.57;95% CI: 0.41-0.74）。此外，尽管KE患者的BHB水平显著高于24小时和72小时KD患者（P< 0.001和P= 0.001），但KD患者的C4-OH异丁基肉碱（尽管不是丁基肉碱）水平高于KE患者（P= 0.018和P= 0.003）。在KEETO-CROSS中，酮/脂肪酸氧化增强和BCAA分解代谢的组合标记物可以强烈预测MGS，具有强大的区分价值，并且在FDG-PET之前的测量中被证明具有实用价值，可以降低假阳性扫描的风险。这些发现表明，加强这些氧化途径的策略，而不是单独增加循环代谢物水平，可能更有效地改善MGS。此外，我们的研究结果显示，KD组的C4-OH异丁基肉碱水平较高，这解释了为什么KE组的BHB水平显著高于KD组的MGS（图1B）。最后，在早期研究中，这些生物标志物可以作为新的替代终点，优先考虑高产MGS技术。局限性包括对健康队列的研究和仅对2种MGS策略的研究。
DECEMBER 2022: 1264–1266 1265 of 0.83 [95% CI: 0.65-1.00] and 0.81 [0.70-0.92], respectively) in all 57 FDG-PET scans, and corresponding odds ratios were 4.93 (95% CI: 0.62-39.43) and 9.59 (95% CI: 3.54-25.97) for MGS per SD increase. Although we previously found that BHB achieved comparable C statistics in the KD and KE arms separately, 2 BHB was not predictive in a combined model (C statistic: 0.57; 95% CI: 0.41-0.74). Furthermore, although BHB levels were significantly higher on KE than the 24-and 72-hour KD visits (P< 0.001 and P= 0.001), C4-OH isobutyrylcarnitine (although not butyrylcarnitine) levels were higher during KD visits than during KE (P= 0.018 and P= 0.003). In KEETO-CROSS, combined markers of enhanced ketone/fatty acid oxidation and BCAA catabolism strongly predicted MGS, had robust discriminatory value, and demonstrated utility in measuring before FDG-PET to reduce the risk of false-positive scans. These findings suggest that strategies to enhance these oxidative pathways, rather than augmenting circulating metabolite levels alone, 1 may be more effective in improving MGS. In addition, our results showing higher C4-OH isobutyrylcarnitine levels with KD explain why, despite achieving substantially higher BHB levels, KE was inferior to KD for MGS (Figure 1B). Finally, these biomarkers may act as novel surrogate endpoints during early-phase studies to prioritize high-yield MGS techniques. Limitations include study of a healthy cohort and study of only 2 MGS strategies.
DOI：
10.1007/s12350-016-0502-7
发表时间：
2017-03
期刊：
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
影响因子：
--
作者：
Osborne MT;Hulten EA;Murthy VL;Skali H;Taqueti VR;Dorbala S;DiCarli MF;Blankstein R
通讯作者：
Blankstein R
影响因子：
6.2
作者：
Selvaraj, Senthil;Seidelmann, Sara B.;Bravo, Paco E.
通讯作者：
Bravo, Paco E.
影响因子：
9.3
作者：
Selvaraj, Senthil;Margulies, Kenneth B.;Dugyala, Supritha;Schubert, Erin;Tierney, Ann;Arany, Zoltan;Pryma, Daniel A.;Shah, Svati H.;Rame, J. Eduardo;Kelly, Daniel P.;Bravo, Paco E.
通讯作者：
Bravo, Paco E.